摘要
目的 观察药物代谢酶系统中CYP2C19基因多态性及患者主要临床资料与服用氯吡格雷前后血小板聚集率变化（氯吡格雷药物抵抗）的相关性。方法 入选拟行冠脉造影检查或支架植入治疗患者35例,根据围手术期应用氯吡格雷前后血小板聚集率变化,将患者分为氯吡格雷抵抗组和非抵抗组。检测CYP2C19基因型,并记录患者年龄、性别、烟酒史、高血压、糖尿病等主要临床资料,分析基因水平及临床水平各因素对血小板聚集及氯吡格雷药物抵抗的影响。结果 检测出氯吡格雷抵抗的患者15例,CYP2C19慢代谢基因型患者4例,Logistic回归分析显示,CYP2C19基因型是氯吡格雷抵抗的危险因素（OR=1.236,95%CI：0.273~5.599,P=0.049）。结论 CYP2C19基因型在基因水平与氯吡格雷抵抗相关,临床水平资料未见明显相关性。
Objective To observe the correlation of CYP2C19 gene polymorphism in drug metabolism enzyme system and main clinical data with the change of platelet aggregation rate before and after taking clopidogrel （ clopdogrel drug resistance ）. Methods Totally 35 patients with coronary angiography examination or stenting treatment were selected and divided into clopidogrel resistance group （resistance group） and the non-resistance group according to the change of platelet aggregation rate before and after taking clopidogrel. CYP2C19 genotype was tested, and the pa- tients＇ age, sex, alcohol tobacco history, hypertension, diabetes and other major clinical data were recorded, and the effect of genetic level and clinical level on platelet aggregation and clopidogrel drug resistance were analyzed. Results There were 15 cases with clopidogrel resistance and 4 cases with CYP2C19 genotype slow metabolism. Logistic regression a- nalysis showed that CYP2C19 genotype was a risk factor for clopidogrel resistance （OR = 1. 236,95% CI：0. 273 5. 599 ,P = 0. 049）. Conclusion CYP2C19 gene polymorphisms are associated with clopidogrel resistance at the genetic level,but clinical level shows no obvious correlation.
出处
《实用药物与临床》
CAS
2016年第9期1097-1100,共4页
Practical Pharmacy and Clinical Remedies
